pharmaphorum13d
Ibrance trial failure dashes Pfizer’s growth hopes for the drug
Ibrance was first approved in 2015 as a treatment for breast cancer patients who had progressed after hormone therapy, and buoyed by expanded use as a first-line therapy has grown swiftly to reach ...
Press Gazette20d
Top 50 news websites in the world: AP and NBC see more than 50% monthly surge
President Donald Trump talks to the media at a public press event following the RNC debate in Houston, Texas in February 2016. Picture: Stock_photo_world/Shutterstock ...
precisionmedicineonline23d
Ibrance Plus Frontline Standard Therapy Delays Progression in HER2, HR-Positive Breast Cancer
SAN ANTONIO – Pfizer's CDK4/6 inhibitor Ibrance (palbociclib) added to standard anti-HER2 and endocrine therapy may become a new standard of care for frontline maintenance treatment of hormone ...
Yahoo Finance26d
SABCS: Pfizer’s IBRANCE combo improves PFS in breast cancer study
Healthcare giant Pfizer’s IBRANCE (palbociclib) as a combination therapy has improved progression-free survival from a Phase III trial in patients with metastatic breast cancer. Unveiled ...
clinicaltrialsarena26d
SABCS: Pfizer’s IBRANCE combo improves PFS in breast cancer study
Results found that IBRANCE was able to see medical profession free survival extended by an additional 15 months. Credit: Shutterstock / ShU studio Healthcare giant Pfizer’s IBRANCE (palbociclib) as a ...
Cancer Research26d
Palbociclib Dramatically Increases PFS in Metastatic Breast Cancer
The CDK4/6 inhibitor palbociclib (Ibrance; Pfizer) led to a significant improvement in progression-free survival (PFS) in patients with HR-positive, HER2-positive metastatic breast cancer when added ...
Yahoo Finance26d
Pfizer's Cancer Drug Ibrance Combo Therapy Extends Median Progression-Free Survival By Over 15 Months In certain Of Breast Cancer Patients
The trial demonstrated that the addition of IBRANCE (palbociclib) to current standard-of-care first-line maintenance therapy (following induction chemotherapy) resulted in statistically ...
ENDPOINTS NEWS26d
Pfiz­er shares pos­i­tive Phase 3 re­sults in breast can­cer sub­set
Pfiz­er touts Ibrance’s sta­tus as a stan­dard of care in HR-pos­i­tive, HER2-neg­a­tive metasta­t­ic breast can­cer. Now the com­pa­ny wants to ex­pand to dou­ble-pos­i­tive pa ...
Benzinga.com26d
Pfizer's Cancer Drug Ibrance Combo Therapy Extends Median Progression-Free Survival By Over 15 Months In certain Of Breast Cancer Patients
Pfizer's PATINA trial shows IBRANCE boosts progression-free survival in HR+/HER2+ metastatic breast cancer by over 15 months. Median PFS reached 44.3 months with IBRANCE plus standard anti-HER2 ...
Yahoo Finance26d
Pfizer's Cancer Drug Ibrance Combo Therapy Extends Median Progression-Free Survival By Over 15 Months In certain Of Breast Cancer Patients
The trial demonstrated that the addition of IBRANCE (palbociclib) to current standard-of-care first-line maintenance therapy (following induction chemotherapy) resulted in statistically significant ...
Investing27d
Pfizer reports extended survival in breast cancer trial
The study showed that adding IBRANCE (palbociclib) to the standard first-line maintenance therapy extended median PFS by over 15 months compared to therapy without IBRANCE. The trial, sponsored by ...